Colorectal cancer (CRC) is the third most common cancer among men and women in the United States (US), with 120,750 new cases and 49,070 deaths reported in 2013.

CRC is the standard gold standard for CRC screening and is the most sensitive and specific method for the detection of CRC and adenomatous polyps. 2

Screening Procedures

- Colonoscopies and sigmoidoscopies were identified using claims data for physicians and/or facilities.
- For each identified procedure, claims data were used to identify patient demographics, geographic location, patient health status, bowel preparation agent, presence of a repeat procedure, and an associated hospitalization.

The logistic regression model found no significant relationship between CRC and these hospitalizations (P=0.32).

Repeat Screening Events

- The rate of repeat colonoscopy or sigmoidoscopy in patients receiving P/MC was not different compared with other patients overall (1.6% vs. 1.5%, respectively) (Table 3).

CONCLUSIONS

- In a real-world study of outcomes associated with bowel cleansing agents, P/MC compared favorably with other LV products, HV products, and other bowel preparations.
- Patients who received P/MC had no hospitalizations with a diagnosis of hypotension, dehydration, or other fluid disorders within 10 days of a colonoscopy/sigmoidoscopy.
- Repeat procedure rates for patients who received P/MC were not significantly different from rates for those who used other bowel preparation products.

Adjusted Analyses

- Adjusted analyses controlling for age, sex, and geographic location showed that repeat procedure rates for patients who received P/MC were not significantly different compared with rates of patients who used any other bowel preparation (Table 5).
- Older age, poorer health status, and female sex were significantly associated with higher rates of early repeat screenings.

Table 5. Factors Associated With increased likelihood of Repeat Procedure

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.06 (1.03-1.08)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>0.86 (0.83-0.89)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HV bowel cleanser</td>
<td>0.91 (0.87-0.96)</td>
<td>0.0037</td>
</tr>
</tbody>
</table>

References


